Founded in 2016 and based in Waltham, Massachusetts, Dragonfly Therapeutics discovers, develops, and commercializes therapies that utilize its proprietary technology to mobilize the body's innate immune system. These therapies counteract immune suppressive factors in the tumor microenvironment and stimulate anti-cancer immune responses. Dragonfly's therapies have the potential to be potent as standalone treatments and in combination with existing cancer immunotherapies, such as T cell treatments.